The TB Alliance established a Scientific Advisory Committee to provide invaluable scientific guidance.
The Scientific Advisory Committee provides technical expertise on drug research, development, manufacturing, and distribution, as well as other medical and scientific issues. It consists of fifteen experts from a wide range of relevant disciplines.
Philip Hipskind
Shefali Kakar
Dale J. Kempf
Carl Nathan
Eric Nuermberger
Jack Reynolds
Stakeholder institutions advise, guide, and support the efforts of TB Alliance.
The TB Alliance Stakeholders Association (SHA) is an advisory committee which provides advice and support to on activities related to the research & development of anti-tuberculosis medicines and regimens; access to new TB products, the fulfilment of TBAlliance’s AAA Mandate – that all new products are adopted, available and affordable; dissemination and sharing of relevant information globally; and to participate in fundraising and advocacy efforts.
The SHA President is elected by active SHA members and serves as a voting ex officio member of the TB Alliance Board of Directors.
- View information about our latest Stakeholders Association meeting
- Apply to join the Stakeholder’s Association
AIDS-Free World
American Lung Association
American Thoracic Society
Amsterdam Institute for Global Health and Development
Burnet Institute
Clinton Health Access Initiative
Eli Lilly and Company
Elizabeth Glaser Pediatric AIDS Foundation
European and Developing Countries Clinical Trials Partnership (EDCTP)
European Commission
FIND
FIOCRUZ
Foundation for Neglected Disease Research (FNDR)
Gates Foundation
GlaxoSmithKline
Global Fund to Fight AIDS, TB and Malaria
Global Health Advocates
Indian Council of Medical Research
Infectious Diseases Society of America
International Tuberculosis Research Center (ITRC)
International Union Against Tuberculosis and Lung Disease
Irish Aid
IS Global
Janssen
Japan Anti-Tuberculosis Association/ Research Institute of Tuberculosis (JATA/RIT)
KNCV Tuberculosis Foundation
Macleods
McGill International TB Centre
National Center for TB Control and Prevention of China Center for Disease Control (NCTB of China CDC)
National Institute for Research in Tuberculosis, India
New Jersey Medical School Global Tuberculosis Institute
Novartis
Open Source Pharma
Partners in Health
Population Services International
Rede Brasileira de Pesquisa em Tuberculose
RESULTS
RTI International
Sanofi
Setshaba Research Centre
South African Medical Research Council
Stop TB Partnership
Swiss Tropical and Public Health Institute
TB Alert
Treatment Action Group (TAG)
TuBerculosis Vaccine Initiative (TBVI)
UIC Institute for Tuberculosis Research
UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases
United Kingdom Foreign, Commonwealth & Development Office (FCDO)
United States Agency for International Development
Our Access Advisory Committee assists in our efforts to lower barriers to access to new TB cures.
The Access Advisory Committee (AAC) assists, supports, and advises the TB Alliance on strategies and approaches to achieve adoption, availability, and affordability of new treatment regimens. The group provides ideas, advice, and contacts offering critical thinking on ways to reduce barriers to access.